3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
3
Sarcoma, Synovial
2
Rhabdomyosarcoma
2
Neurofibrosarcoma
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Hemangiosarcoma
2
Fibrosarcoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Ovarian Neoplasms
1
Malignant mesenchymal tumor
1
Liposarcoma, Myxoid
1
Hemangiopericytoma, Malignant
1
Gastrointestinal Stromal Tumors
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Trabectedin
3
Radiation Dose Hypofractionation
3
Cyclophosphamide
3
fludarabine
2
ribociclib
1
pembrolizumab
1
interferon gamma-1b
1
cytochrome C synthetase
1
brostallicin
1
atezolizumab
1
Sirolimus
1
Pioglitazone
1
Interferon-gamma
1
Diathermy
1
Dexamethasone
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liposarcoma, Myxoid
×
brostallicin
×
Clear all
NCT00633165
2010-02-26
SMI-BRS-202
Systems Medicine LLC
Phase 2
Unknown
24 enrolled